STOCK TITAN

Jaguar Health Inc - JAGX STOCK NEWS

Welcome to our dedicated page for Jaguar Health news (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health stock.

Jaguar Health Inc (NASDAQ: JAGX) delivers innovative plant-based therapeutics for gastrointestinal health across human and animal populations. This news hub provides investors and healthcare professionals with essential updates about the company’s clinical developments, regulatory milestones, and sustainable pharmaceutical innovations.

Access official press releases and verified news covering key areas including FDA approvals for Mytesi® (crofelemer), veterinary health product developments like Canalevia™, clinical trial progress, and strategic partnerships. Our curated collection ensures timely updates on JAGX’s advancements in non-opioid anti-secretory treatments and ecological sourcing practices.

Discover updates across multiple categories: new product launches, research collaborations, financial disclosures, intellectual property developments, and sustainability initiatives. Each update is vetted for accuracy, providing reliable insights into Jaguar Health’s progress in addressing chronic diarrhea conditions and neglected gastrointestinal disorders.

Bookmark this page for streamlined access to Jaguar Health’s latest developments. Check back regularly for updates on their unique approach to combining traditional botanical knowledge with modern pharmaceutical science through subsidiaries like Napo Pharmaceuticals.

Rhea-AI Summary

Jaguar Health (NASDAQ:JAGX) announced significant findings related to cancer-related diarrhea (CRD) through its subsidiary, Napo Pharmaceuticals. Three abstracts have been accepted for presentation at the ASCO Annual Meeting from June 4-8, 2021. Key findings show that patients with CRD are 40% more likely to discontinue chemotherapy, leading to increased healthcare resource utilization and costs, with those affected incurring nearly 2.9 times higher costs than non-CRD patients. The need for effective CRD management is emphasized to enhance treatment adherence.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.04%
Tags
none
-
Rhea-AI Summary

Jaguar Health (NASDAQ:JAGX) has launched a new Instagram page to foster community engagement and awareness. The platform will host jaguar-themed contests and provide educational content related to plant-based medicines and environmental conservation. A caption contest will run until May 26, with submissions judged by a panel including the company's CEO. Additionally, the page will promote activities in recognition of HIV Long-Term Survivors Awareness Day on June 5. Jaguar is focused on developing plant-based drugs for gastrointestinal issues.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.03%
Tags
none
-
Rhea-AI Summary

Jaguar Health (NASDAQ:JAGX) has announced progress on its Canalevia drug candidate, the first FDA-approved plant-based medicine for treating chemotherapy-induced diarrhea (CID) in dogs. With over 50,000 dogs experiencing CID annually, Canalevia aims to provide relief for these pets during cancer treatment. The company plans to submit applications for conditional approval by Q4 2021. Additionally, Jaguar is working on approval for exercise-induced diarrhea (EID) in working dogs. Canalevia is positioned to enhance the quality of life for dogs undergoing chemotherapy, benefiting pet owners and veterinary teams alike.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.81%
Tags
none
Rhea-AI Summary

Jaguar Health, Inc. (NASDAQ:JAGX) announced the granting of nonstatutory stock options and restricted stock units (RSUs) to three new employees as inducement awards effective May 12, 2021. The stock options total 48,750 shares with an exercise price of $1.22, vesting over three years. The RSUs granted to one employee total 2,375 shares, also vesting over three years. These awards aim to incentivize new hires as part of the Company’s growth strategy, reflecting a commitment to attract talent in the pharmaceuticals sector.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.15%
Tags
management
-
Rhea-AI Summary

Jaguar Health, Inc. (NASDAQ:JAGX) announced that its Annual Meeting of Stockholders, originally held on May 13, 2021, was adjourned due to a lack of quorum, with a reconvene scheduled for June 11, 2021, at 8:30 AM PST. Over 80% of votes cast favored Proposals 2, 3, 4, and 6. Proposal 3 aims to increase the authorized shares of Common Stock from 150 million to 290 million, providing flexibility for future business opportunities. Stockholders are encouraged to participate in the voting process as approximately 11% of eligible shares are still needed to reach quorum.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.48%
Tags
none
-
Rhea-AI Summary

Jaguar Health (NASDAQ:JAGX) announced a webcast to discuss Q1 2021 financial results and business updates on May 17, 2021, at 8:30 AM ET. Interested participants can register using the provided link. Jaguar is focused on developing plant-based medicines for gastrointestinal issues, particularly chronic diarrhea. Its product, Mytesi (crofelemer), is FDA-approved for noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company emphasizes sustainable practices in harvesting its active ingredients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.78%
Tags
conferences
Rhea-AI Summary

Jaguar Health, Inc. (NASDAQ:JAGX) announced a registered direct offering of 7,647,000 shares, raising approximately $10.8 million. The offering price is set at $1.41 per share, with proceeds aimed at supporting its subsidiary Napo EU S.p.A. This includes potential capital expenditures, licenses, acquisitions, and growth opportunities. The company also terminated its at-the-market financing program effective April 26, 2021. Closing is expected around May 3, 2021, pending customary conditions satisfaction.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.43%
Tags
-
Rhea-AI Summary

Jaguar Health (NASDAQ:JAGX) announced that an abstract on patient outcomes related to cancer therapy-related diarrhea was accepted for a poster presentation at the 2021 ASCO Annual Meeting, occurring virtually from June 4-8, 2021. The study, titled The impact of cancer-related diarrhea on changes in cancer therapy patterns: Real world evidence, highlights the significance of diarrhea in cancer treatment. Napo Pharmaceuticals, Jaguar's subsidiary, is conducting a pivotal Phase 3 clinical trial of crofelemer (Mytesi), aimed at preventing diarrhea in cancer patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.43%
Tags
none
-
Rhea-AI Summary

Jaguar Health, Inc. (JAGX) has announced a webcast interview featuring CEO Lisa Conte and Dragon SPAC lead sponsor Josh Mailman on April 23, 2021, at 8:30 AM Eastern. The discussion will cover the business overview of Napo EU S.p.A., its wholly owned Italian subsidiary. The Company is seeking conditional marketing authorization from the European Medicines Agency for crofelemer to treat COVID-related diarrhea. Jaguar is focused on developing sustainable, plant-based pharmaceuticals for gastrointestinal distress.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.68%
Tags
none
Rhea-AI Summary

Jaguar Health, Inc. (NASDAQ:JAGX) announced a webcast interview on April 23, 2021, at 8:30 AM Eastern, featuring CEO Lisa Conte, aimed at providing an overview of Napo EU S.p.A., its Italian subsidiary. The company has also launched a rebranded Napo EU website, showcasing a new logo and promising expanded content. Mytesi®, Jaguar's key product, is the only FDA-approved plant-based medication for noninfectious diarrhea in adults with HIV/AIDS. The company focuses on developing sustainable plant-based pharmaceuticals for gastrointestinal issues.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.62%
Tags
none
Jaguar Health Inc

Nasdaq:JAGX

JAGX Rankings

JAGX Stock Data

3.71M
576.85k
14.81%
1.71%
5.81%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN FRANCISCO